The expression of β-catenin S33A, a frequently occurring site mutation of β-catenin in cancers [39], could partially rescue the proliferation and invasion of breast cancer cells treated with arctigenin (Figure 5C–E and Supplementary Figure S3B,C), while GM-CSF and TSLP dual treatment could completely rescue the proliferation and invasion (Figure 5C–E and Supplementary Figure S3B,C). This evidence concerns the gene CSF2 and breast carcinoma.